Boerth Jeffrey A, Schimpl Marianne, Lucas Simon C C, Zhang Jingwen, Code Erin L, Embrey Kevin J, Rawlins Philip B, Wang Haixia, Storer R Ian, Di Fruscia Paolo, Nelson Jennifer E, Milbradt Alexander G, Börjesson Ulf, Gohlke Andrea, Korboukh Victoria, Gopalsamy Ariamala
Medicinal Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
Protein, Structure and Biophysics, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
ACS Med Chem Lett. 2025 May 8;16(6):1073-1079. doi: 10.1021/acsmedchemlett.5c00120. eCollection 2025 Jun 12.
Suppression of oncogenic gene expression is an effective strategy for the treatment of cancer. The SWI/SNF (SWItch/Sucrose Non-Fermentable) complex plays an important role in regulating gene activation or repression, and its dysregulation has been linked to aberrant transcription activity in many types of cancer. Targeting the subunits of this complex, such as SMARCA2, SMARCA4, and PBRM1, which are part of the bromodomain family VIII, has significant therapeutic potential. Herein we report the discovery of pyrimidoindolones as a novel series of bromodomain family VIII binders identified through an NMR-based fragment screen. These binders have been optimized to achieve sub-μM affinity for the family VIII proteins SMARCA2, SMARCA4, and PRBM1, with promising physicochemical properties.
抑制致癌基因表达是治疗癌症的有效策略。SWI/SNF(开关/蔗糖非发酵)复合物在调节基因激活或抑制中起重要作用,其失调与多种癌症中的异常转录活性有关。靶向该复合物的亚基,如属于溴结构域家族VIII的SMARCA2、SMARCA4和PBRM1,具有显著的治疗潜力。在此,我们报告通过基于核磁共振的片段筛选发现嘧啶吲哚酮作为新型的溴结构域家族VIII结合剂。这些结合剂已经经过优化,对家族VIII蛋白SMARCA2、SMARCA4和PRBM1具有亚微摩尔亲和力,并具有良好的物理化学性质。